Earnings Feed
Start Free
Home/Filings/4/0001209191-14-022403
4//SEC Filing

CADENCE PHARMACEUTICALS INC 4

Accession 0001209191-14-022403

CIK 0001333248operating
View on SEC.govCompany Profile

Filed

Mar 20, 8:00 PM ET

Accepted

Mar 21, 1:47 PM ET

Size

18.6 KB

Accession

0001209191-14-022403

Insider Transaction Report

Form 4
Period: 2014-03-19
CADENCE PHARMACEUTICALS INCCADX
Rich Todd W
Director
Transactions
  • Disposition to Issuer

    stock option (right to buy)

    2014-03-19$4.63/sh−12,500$57,875→ 0 total
    Exercise: $9.37Exp: 2019-06-23→ common stock (12,500 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2014-03-19$6.79/sh−25,000$169,750→ 0 total
    Exercise: $7.21Exp: 2021-06-15→ common stock (25,000 underlying)
  • Disposition from Tender

    common stock

    2014-03-19$14.00/sh−10,000$140,000→ 0 total(indirect: By Trust)
  • Disposition to Issuer

    stock option (right to buy)

    2014-03-19$4.08/sh−25,000$102,000→ 0 total
    Exercise: $9.92Exp: 2018-08-25→ common stock (25,000 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2014-03-19$6.84/sh−12,500$85,500→ 0 total
    Exercise: $7.16Exp: 2020-06-16→ common stock (12,500 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2014-03-19$4.75/sh−12,500$59,375→ 0 total
    Exercise: $9.25Exp: 2021-06-15→ common stock (12,500 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2014-03-19$11.02/sh−17,500$192,850→ 0 total
    Exercise: $2.98Exp: 2022-06-13→ common stock (17,500 underlying)
Footnotes (2)
  • [F1]Dr. Rich is a trustee of this trust.
  • [F2]In connection with the merger of Cadence Pharmaceuticals, Inc. ("Cadence") with Madison Merger Sub, Inc. ("Merger Sub") on March 19, 2014, and pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") by and among Cadence, Mallinckrodt plc ("Parent") and Merger Sub, dated February 10, 2014, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (a) the number of shares of common stock of Cadence underlying such option multiplied by (b) the excess, if any, of $14.00 (the "Offer Price") over the exercise price per share of such option.

Documents

1 file

Issuer

CADENCE PHARMACEUTICALS INC

CIK 0001333248

→
Entity typeoperating

Related Parties

1
  • filerCIK 0001333248

Filing Metadata

Form type
4
Filed
Mar 20, 8:00 PM ET
Accepted
Mar 21, 1:47 PM ET
Size
18.6 KB
View on SEC.gov